American Lawyer |
Subscription Required |
February 7, 2013
Ted Frank, the conservative legal activist and bane of allegedly unfair class action settlements, has picked yet another target. This time, it's a $15 million deal that Bayer Corp. reached in May with customers who accused the company selling overpriced and non-FDA approved aspirin.
Fewer than 20,000 class members have bothered to go through the arduous claim procedures in the Bayer Corp. class action, which caps recovery for most of those class members at $4 unless they saved several-year-old receipts for aspirin products. But the attorneys—led by Hagens Berman—are asking for $5.1 million for themselves.
Companies Bill 2011, which was recently passed by the Lok Sabha, prescribes several new guidelines for corporate governance. The one that permits filing class action suits against companies has, in particular, raised curiosity amongst businesses and the public.
The U.S. Supreme Court will soon hear arguments in a case that tests a philosophical question at the heart of modern tort law: If the cost of pursuing a lawsuit exceeds its value to an individual plaintiff, is that a bad thing?
A groundbreaking proposal in Britain making it easier to bring antitrust class actions has business groups worldwide fearful that London will become a center for litigation abuses.
Financial Times |
Subscription Required |
February 4, 2013
The White House is set to order stronger cybersecurity measures by the end of this month as a rash of unprecedented cyber attacks against financial institutions and energy companies are prompting some big companies to rethink the need for government intervention.
Wall Street Journal |
Subscription Required |
February 1, 2013
The maker of Zoloft is being sued in an unusual case alleging the popular antidepressant has no more benefit than a dummy pill and that patients who took it should be reimbursed for their costs.
American Lawyer |
Subscription Required |
February 1, 2013
On Wednesday a federal judge in Newark granted class certification in the eight-year-old case, which accuses Merck and certain executives of overstating the commercial promise of Vioxx despite its health risks.
There were a number of significant class action developments in Canada in 2012, including the “landmark” $117 million E&Y settlement in the Sino-Forest case. The developments during the past year “suggest that 2013 may be a tipping point for the maturing class action jurisprudence in Canada.”